Lucid Diagnostics Analyst Ratings
Lucid Diagnostics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 106.61% | Needham | $2.8 → $2.5 | Maintains | Buy |
| 09/26/2023 | 230.58% | Cantor Fitzgerald | → $4 | Reiterates | Overweight → Overweight |
| 08/22/2023 | 230.58% | Cantor Fitzgerald | → $4 | Reiterates | Overweight → Overweight |
| 08/16/2023 | 230.58% | Cantor Fitzgerald | → $4 | Reiterates | Overweight → Overweight |
| 08/16/2023 | 131.4% | Needham | → $2.8 | Reiterates | Buy → Buy |
| 05/17/2023 | 230.58% | Cantor Fitzgerald | $4.5 → $4 | Maintains | Overweight |
| 05/17/2023 | 131.4% | Needham | $2.6 → $2.8 | Maintains | Buy |
| 04/21/2023 | 114.88% | Needham | → $2.6 | Reiterates | → Buy |
| 03/14/2023 | 114.88% | Needham | $3.1 → $2.6 | Maintains | Buy |
| 11/18/2022 | 189.26% | BTIG | $5 → $3.5 | Maintains | Buy |
| 11/15/2022 | 156.2% | Needham | $4.25 → $3.1 | Maintains | Buy |
| 08/16/2022 | 251.24% | Needham | $5 → $4.25 | Maintains | Buy |
| 05/12/2022 | 313.22% | Needham | $7 → $5 | Maintains | Buy |
| 03/29/2022 | 891.74% | Canaccord Genuity | $18 → $12 | Maintains | Buy |
| 03/29/2022 | 478.51% | Needham | $13 → $7 | Maintains | Buy |
| 12/27/2021 | 1222.31% | Ascendiant Capital | → $16 | Initiates Coverage On | → Buy |
| 12/15/2021 | 974.38% | Needham | $17 → $13 | Maintains | Buy |
| 11/08/2021 | 1057.02% | BTIG | → $14 | Initiates Coverage On | → Buy |
| 11/08/2021 | 1387.6% | Canaccord Genuity | → $18 | Initiates Coverage On | → Buy |
| 11/08/2021 | 1635.54% | Cantor Fitzgerald | → $21 | Initiates Coverage On | → Overweight |
| 11/08/2021 | 1304.96% | Needham | → $17 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/14/2023 | 106.61% | 尼德姆 | 2.8 美元 → 2.5 美元 | 维护 | 买 |
| 09/26/2023 | 230.58% | 坎托·菲茨杰拉德 | → 4 美元 | 重申 | 超重 → 超重 |
| 08/22/2023 | 230.58% | 坎托·菲茨杰拉德 | → 4 美元 | 重申 | 超重 → 超重 |
| 08/16/2023 | 230.58% | 坎托·菲茨杰拉德 | → 4 美元 | 重申 | 超重 → 超重 |
| 08/16/2023 | 131.4% | 尼德姆 | → 2.8 美元 | 重申 | 购买 → 购买 |
| 05/17/2023 | 230.58% | 坎托·菲茨杰拉德 | 4.5 美元 → 4 美元 | 维护 | 超重 |
| 05/17/2023 | 131.4% | 尼德姆 | 2.6 美元 → 2.8 美元 | 维护 | 买 |
| 04/21/2023 | 114.88% | 尼德姆 | → 2.6 美元 | 重申 | → 购买 |
| 03/14/2023 | 114.88% | 尼德姆 | 3.1 美元 → 2.6 美元 | 维护 | 买 |
| 11/18/2022 | 189.26% | BTIG | 5 美元 → 3.5 美元 | 维护 | 买 |
| 11/15/2022 | 156.2% | 尼德姆 | 4.25 美元 → 3.1 美元 | 维护 | 买 |
| 08/16/2022 | 251.24% | 尼德姆 | 5 美元 → 4.25 美元 | 维护 | 买 |
| 05/12/2022 | 313.22% | 尼德姆 | 7 美元 → 5 美元 | 维护 | 买 |
| 03/29/2022 | 891.74% | Canaccord Genu | 18 美元 → 12 美元 | 维护 | 买 |
| 03/29/2022 | 478.51% | 尼德姆 | 13 美元 → 7 美元 | 维护 | 买 |
| 2021 年 12 月 27 日 | 1222.31% | 上升资本 | → 16 美元 | 启动覆盖范围开启 | → 购买 |
| 2021 年 12 月 15 日 | 974.38% | 尼德姆 | 17 美元 → 13 美元 | 维护 | 买 |
| 2021 年 8 月 11 日 | 1057.02% | BTIG | → 14 美元 | 启动覆盖范围开启 | → 购买 |
| 2021 年 8 月 11 日 | 1387.6% | Canaccord Genu | → 18 美元 | 启动覆盖范围开启 | → 购买 |
| 2021 年 8 月 11 日 | 1635.54% | 坎托·菲茨杰拉德 | → 21 美元 | 启动覆盖范围开启 | → 超重 |
| 2021 年 8 月 11 日 | 1304.96% | 尼德姆 | → 17 美元 | 启动覆盖范围开启 | → 购买 |
What is the target price for Lucid Diagnostics (LUCD)?
Lucid Diagnostics（LUCD）的目标价格是多少？
The latest price target for Lucid Diagnostics (NASDAQ: LUCD) was reported by Needham on November 14, 2023. The analyst firm set a price target for $2.50 expecting LUCD to rise to within 12 months (a possible 106.61% upside). 11 analyst firms have reported ratings in the last year.
Needham于2023年11月14日公布了Lucid Diagnostics（纳斯达克股票代码：LUCD）的最新目标股价。该分析公司将目标股价定为2.50美元，预计LUCD将在12个月内升至12个月内（可能上涨106.61％）。去年有11家分析公司公布了评级。
What is the most recent analyst rating for Lucid Diagnostics (LUCD)?
分析师对Lucid Diagnostics（LUCD）的最新评级是多少？
The latest analyst rating for Lucid Diagnostics (NASDAQ: LUCD) was provided by Needham, and Lucid Diagnostics maintained their buy rating.
Lucid Diagnostics（纳斯达克股票代码：LUCD）的最新分析师评级由Needham提供，Lucid Diagnostics维持买入评级。
When is the next analyst rating going to be posted or updated for Lucid Diagnostics (LUCD)?
Lucid Diagnostics（LUCD）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lucid Diagnostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lucid Diagnostics was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Lucid Diagnostics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Lucid Diagnostics的最新评级是在2023年11月14日公布的，因此您应该预计下一个评级将在2024年11月14日左右公布。
Is the Analyst Rating Lucid Diagnostics (LUCD) correct?
分析师评级 Lucid Diagnostics (LUCD) 正确吗？
While ratings are subjective and will change, the latest Lucid Diagnostics (LUCD) rating was a maintained with a price target of $2.80 to $2.50. The current price Lucid Diagnostics (LUCD) is trading at is $1.21, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Lucid Diagnostics（LUCD）评级维持不变，目标股价为2.80美元至2.50美元。Lucid Diagnostics（LUCD）目前的交易价格为1.21美元，超出了分析师的预期区间。